• Publications
  • Influence
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
TLDR
Her2 imaging is feasible during trastuzumab treatment as the receptor might be saturated and the residence times of normal organs remained similar except for the cardiac blood pool. Expand
(89)zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients.
TLDR
Whether GC1008 uptake in brain tumors can be visualized using the 89Zirkonium (Zr)-GC1008 PET scan and to assess treatment outcome in patients with recurrent glioma treated with GC 1008 (NCT01472731) is investigated. Expand
89 Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP 90 Inhibitor NVP-AUY 922
1Department of Medical Oncology, University of Groningen, Groningen, The Netherlands; 2Department of Pathology, University of Groningen, Groningen, The Netherlands; 3Department of Nuclear MedicineExpand
CXCR 4 Inhibition with AMD 3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy 1
Several in vitro and in vivo models have revealed the key role of CXCR4/CXCL12 axis in tumor-stroma interactions. Stromal cells present in the tumor microenvironment express high levels of CXCL12Expand
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment.
TLDR
Her2 imaging is feasible during trastuzumab treatment as the receptor might be saturated and the residence times of normal organs remained similar except for the cardiac blood pool. Expand
89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.
TLDR
To visualize VEGF, serial 89Zr-bevacizumab-PET scans before and during antiangiogenic treatment in RCC patients were performed and 131 out of 231 lesions ≥ 10 mm (detection limit) were visible and 125 quantifiable. Expand
...
1
2
3
...